Biotechnologie & Biologie Synthétique
Programmation du vivant : CRISPR, protein design, biofoundries, biomaterials
Vue d'ensemble
Programmation et engineering du vivant. CRISPR thérapies géno, protéines designées, fermentation biologique, matériaux bio inspirés.
Impact : Cure de maladies génétiques, bioproduction échelle exajoule, nouveaux matériaux, zéro-waste manufacturing
Acteurs impliqués
Projets
En cours
Editas Medicine — CRISPR Gene Therapy
Editas
Pipeline 20+ indications. First approvals 2024-2025, expansion agressive 2026+.
CRISPR thérapies cliniques. Maladies héréditaires, cancers, infections.
- CRISPR delivery
- Clinical trials
- Rare disease indication
- Manufacturing
Feuille de route: Approvals multiples indications
2025-2026
DeepMind — AlphaFold & Protein Design
DeepMind/Google
AlphaFold tous les problèmes. Drug discovery acceleration massif. Therapeutics custom-designed.
AlphaFold3 structure prediction. Protein design ab initio. Therapeutics pipeline.
- AlphaFold3
- Protein design
- Drug discovery
- Biologics
- Academic releases
Feuille de route: First AlphaFold-discovered drug Phase 3
2027-2028
Intrexon (Precigen) — Biomanufacturing
Precigen / Intrexon
Bio-manufacturing scale. Chemicals, fuels, materials via fermentation optimized.
Biofoundries de production. Yeast, algae, bacteria pour produits industriels.
- Strain engineering
- Fermentation optimization
- Industrial scale
- Product portfolio
- Cost reduction
Feuille de route: Gigaton-scale produktion
2027-2028
Mylo & Bolt Threads — Biomaterials
Bolt Threads
Production de matériaux impossibles via fermentation. Mode durable, haute performance.
Matériaux biosynthétiques. Mylo (mushroom leather), spider silk proteins, performance textiles.
- Mycelium cultivation
- Silk protein production
- Textile manufacturing
- Durability
Feuille de route: Production scale 1000 tonnes/an
2026-2027
Genentech & Collaborators — mRNA Therapeutics
Genentech / Roche
Expansion au-delà COVID. RSV approval, influenza clinical data, cancer vaccines Phase 2/3.
mRNA platforms post-COVID. Vaccines, cancers, monogenic diseases.
- mRNA platform
- Lipid nanoparticles
- Vaccine development
- Cancer immunity
Feuille de route: Multiple cancer vaccine approvals
2026-2027